{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Generic Brands and Products", "name": "subject", "rank": "2", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/05/19/opinion/the-generic-drug-market.html", "document_type": "article", "byline": [], "type_of_material": "Letter", "multimedia": [], "section_name": "Opinion", "word_count": "255", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The Healthcare Supply Chain Association says the backlog of new generic drug applications at the F.D.A. is compounding the problem of price increases.", "pub_date": "2016-05-19T00:00:00Z", "news_desk": "Letters", "headline": {"kicker": "Letter", "main": "The Generic Drug Market", "content_kicker": "Letter"}, "print_page": null, "snippet": "The Healthcare Supply Chain Association says the backlog of new generic drug applications at the F.D.A. is compounding the problem of price increases.", "_id": "573c916038f0d86c87c2cefb", "slideshow_credits": null, "abstract": null}